Atara Biotherapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net income (loss) | $(8,979) | $40,397 |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Stock-based compensation expense | 1,143 | 7,010 |
| Depreciation and amortization expense | 43 | 2,031 |
| Accretion of liability related to sale of future revenues | 987 | 1,809 |
| Amortization (accretion) of investment premiums (discounts) | (29) | 258 |
| Non-cash operating lease expense | 376 | 4,413 |
| Loss on impairment of lease right-of-use asset | — | 4,130 |
| Gain on derecognition of lease liabilities | — | (1,167) |
| Other non-cash items, net | 100 | 547 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 935 | 1,482 |
| Inventories | — | 10,655 |
| Other current assets | (862) | 6,211 |
| Other assets | 110 | (4) |
| Accounts payable | 697 | (3,066) |
| Accrued compensation | (572) | (4,037) |
| Accrued research and development expenses | (25) | (7,013) |
| Other current liabilities | 81 | (1,438) |
| Deferred revenue | 59 | (93,485) |
| Operating lease liabilities | (496) | (4,190) |
| Other long-term liabilities | 21 | 1 |
| Net cash used in operating activities | (6,411) | (35,456) |
| Investing activities | ||
| Purchases of short-term investments | (6,626) | (5,419) |
| Proceeds from maturities and sales of short-term investments | — | 17,199 |
| Proceeds from sale of property and equipment | — | 349 |
| Net cash (used in) provided by investing activities | (6,626) | 12,129 |
| Financing activities | ||
| Proceeds from issuance of common stock through ATM facilities, net | 7,776 | — |
| Proceeds from sale of pre-funded warrants to purchase common stock in an underwritten registered direct offering or registered direct offering, net | — | 15,304 |
| Proceeds from employee stock awards | — | 1 |
| Principal payments on finance lease obligations | — | (250) |
| Other financing activities, net | — | (1) |
| Net cash provided by financing activities | 7,776 | 15,054 |
| Increase (decrease) in cash, cash equivalents and restricted cash | (5,261) | (8,273) |
| Cash, cash equivalents and restricted cash at beginning of period | 8,482 | 25,176 |
| Cash, cash equivalents and restricted cash at end of period | $3,221 | $16,903 |
| Non-cash financing activities | ||
| Issuance of pre-funded warrants in connection with HCRx Amendment | $1,672 | $— |
| Accrued costs related to underwritten registered direct offering | $— | $461 |
| Accrued costs related to ATM facility | $103 | $— |
| Supplemental cash flow disclosure | ||
| Cash paid for interest | $229 | $118 |
| Cash paid for income taxes | $1 | $3 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.